How big is TELA Bio, Inc.?

As of Jun 18, TELA Bio, Inc. has a market capitalization of 59.33 million, with net sales of 71.22 million and a net profit of -43.44 million over the latest four quarters. Shareholder's funds are 28.46 million, and total assets amount to 87.33 million as of Dec 24.

As of Jun 18, TELA Bio, Inc. has a market capitalization of 59.33 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 71.22 million for the latest four quarters. However, it also recorded a net profit of -43.44 million during the same period.<BR><BR>As of Dec 24, the reporting period for the balance sheet shows shareholder's funds of 28.46 million and total assets amounting to 87.33 million.

What does TELA Bio, Inc. do?

TELA Bio, Inc. is a medical technology company that develops tissue reinforcement materials for soft tissue reconstruction. As of March 2025, it reported net sales of $19 million and a net loss of $11 million, with a market cap of $59.33 million.

Overview:<BR>TELA Bio, Inc. is a medical technology company focused on designing, developing, and marketing tissue reinforcement materials for soft tissue reconstruction, operating within the Pharmaceuticals & Biotechnology industry and categorized as a Micro Cap.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 19 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -11 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 59.33 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.06 <BR>Return on Equity: -239.72% <BR>Price to Book: 3.27<BR><BR>Contact Details:<BR>Address: 1 Great Valley Pkwy Ste 24, MALVERN PA: 19355-1423 <BR>Tel: 1 484 3202930 <BR>Fax: 1 302 6555049 <BR>Website: http://www.telabio.com/

Should I buy, sell or hold TELA Bio, Inc.?

Who are in the management team of TELA Bio, Inc.?

As of March 2022, TELA Bio, Inc.'s management team includes Independent Chairman Mr. Douglas Evans, President and CEO Mr. Antony Koblish, and several Independent Directors: Mr. Kurt Azarbarzin, Mr. Vince Burgess, Ms. Lisa Colleran, Ms. Federica O'Brien, and Ms. Adele Oliva. This diverse team guides the company's governance and strategy.

As of March 2022, the management team of TELA Bio, Inc. includes the following individuals:<BR><BR>- Mr. Douglas Evans, who serves as the Independent Chairman of the Board.<BR>- Mr. Antony Koblish, who is the President, Chief Executive Officer, Co-Founder, and Director.<BR>- Mr. Kurt Azarbarzin, who is an Independent Director.<BR>- Mr. Vince Burgess, who is also an Independent Director.<BR>- Ms. Lisa Colleran, serving as an Independent Director.<BR>- Ms. Federica O'Brien, who is an Independent Director.<BR>- Ms. Adele Oliva, who is an Independent Director.<BR><BR>This team comprises a mix of leadership roles and independent directors, contributing to the governance and strategic direction of the company.

Is TELA Bio, Inc. technically bullish or bearish?

As of September 10, 2025, TELA Bio, Inc. has shifted to a bearish trend, indicated by negative signals from MACD, moving averages, and Bollinger Bands, while underperforming the S&P 500 with a year-to-date return of -47.35%.

As of 10 September 2025, the technical trend for TELA Bio, Inc. has changed from mildly bearish to bearish. The current technical stance is bearish, driven by a bearish MACD on the weekly timeframe, bearish moving averages on the daily timeframe, and a bearish signal from the Bollinger Bands on the monthly timeframe. Additionally, the KST and OBV indicators are both showing bearish trends on the monthly timeframe. <BR><BR>In terms of performance, TELA Bio has significantly underperformed the S&P 500 across all multi-period returns, with a year-to-date return of -47.35% compared to the S&P 500's 12.22%.